Roche GLP-1R / GIPR agonist pib qhov kev sim tshuaj rau theem III
Thaum Lub Ib Hlis 20, 2026, raws li US Clinical Trial Registry lub vev xaib, Roche tau tshaj tawm thawj theem II1 kev sim tshuaj ntawm RO7795068 (CT-388).
GLP-1 Txhaj
1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Tablet
(3) Capsule
(4) Txhaj tshuaj
(5) Ua kua dej
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
GLP-1 CAS Nr .: 87805-34-3
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muab GLP-1 Txhaj, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
RO7795068 yog peptide GLP-1R / GIPR agonist tsim los ntawm Carmot Therapeutics. Thaum Lub Kaum Ob Hlis 2023, Roche tau txais Carmot Therapeutics rau $ 3.1 billion, tau txais ntau yam tshuaj insulinotropic hauv plab hauv qab lub tuam txhab lub kaus.
Phase I research data shows that among obese or overweight subjects without type 2 diabetes, RO7795068 can reduce their weight by 18.8% (adjusted by the placebo group) after 24 weeks of treatment, and the proportion of subjects whose weight loss is>5%,>10%, 15%, and>20% yog 100%, 85%, 70%, thiab 45% feem.
Hauv cov neeg rog rog lossis rog rog uas muaj ntshav qab zib hom 2, RO7795068 txo qis HbA1C qib los ntawm 3.0% thiab lub cev hnyav los ntawm 8.6% tom qab 12 lub lis piam kho.
Phase I kawm tau pib lub sijhawm no yog kev sib tw, ob npaug - dig muag, placebo- tswj kev sim tshuaj (n=1600) los ntsuas qhov ua tau zoo thiab kev nyab xeeb ntawm RO7795068 hauv kev kho cov neeg mob rog lossis rog rog nrog hom 2 mob ntshav qab zib.
Lub ntsiab lus kawg ntawm txoj kev tshawb no yog qhov feem pua ntawm cov kev hloov hauv lub cev hnyav ntawm 72 lub lis piam los ntawm qhov pib.
Geli lub cim tshiab GLP-1 triple lub hom phiaj agonist ASC37 tau tsim kho kho mob thiab npaj yuav thov rau IND kev pom zoo hauv Tebchaws Meskas
Thaum Lub Ib Hlis 20, 2026, Geli Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange code: 1672, abbreviated as "Geli") tau xaiv cov tiam tshiab ntawm GLP-1R / GIPR / GCGR triple target agonist peptide ASC37 txhaj rau kev tswj hwm subcutaneous ib hlis ib zaug. Geli xav tias yuav xa daim ntawv thov IND rau ASC37 txhaj tshuaj rau kev kho mob rog rog rau US Food and Drug Administration (FDA) hauv lub quarter thib ob ntawm 2026.
ASC37 yog GLP-1R, GIPR, thiab GCGR triple lub hom phiaj agonist peptide ntawm nws tus kheej tsim los ntawm Artificial Intelligence assisted Structure Based Drug Discovery (ASBDD) thiab Ultra Long Acting Drug Development Platform (ULAP) technologies ntawm Geli. Cov txiaj ntsig kev sim tau pom tias ASC37 yog qhov nruab nrab kwv yees li 5 zaug, 4 zaug, thiab 4 zaug muaj zog dua li retatrutide raws li nws cov kev ua si excitatory rau GLP-1R, GIPR, thiab GCGR, feem. Piv nrog rau kev tswj hwm txhua lub limtiam ntawm rettrutide, ASC37, uas tau tsim thiab ua kom zoo, ua tiav ib nrab ntawm lub neej ntev (tseem ntsuas raws li lub sijhawm xav tau rau cov ntshav cov tshuaj concentration poob mus rau 50% ntawm Cmax), yog li txhawb kev tswj hwm subcutaneous ib hlis ib zaug nrog kev txhaj tshuaj tsis pub tshaj 1 milliliter. Cov kev ua kom zoo tshaj plaws no pab kom txo qis qhov zoo ntawm kev tsim khoom rau kev tsim khoom loj.
Roche qhov ncauj GLP-1 receptor agonist chav kawm 1 cov tshuaj tshiab tau pom zoo rau kev siv tshuaj hauv Suav teb
Thaum Lub Ib Hlis 20, 2026, lub vev xaib raug cai ntawm Lub Chaw Saib Xyuas Tshuaj Ntsuam Xyuas Tshuaj (CDE) ntawm Tuam Tshoj National Medical Products Administration tau tshaj tawm tias Roche's Class 1 cov tshuaj tshiab RO7795081 tau raug pom zoo rau kev siv tshuaj hauv Suav teb thiab yog npaj rau lub sijhawm ntev - tswj qhov hnyav hauv cov neeg mob rog rog lossis rog. Cov ntaub ntawv pej xeem qhia tau hais tias RO7795081 (CT-996) yog qhov ncauj glucagon zoo li peptide-1 (GLP-1) receptor agonist. RO7795081 (CT-996) yog lub qhov ncauj me me molecule GLP1R agonist Ameslikas tsim los ntawm Carmot Corporation. Thaum kawg ntawm 2023, Roche tau txais Carmot rau $ 3.1 nphom, tau txais tom kawg peb qhov kev kho mob theem GLP-1 cov tshuaj tshiab, suav nrog GLP-1 / GIP dual receptor agonist CT-388, qhov ncauj me me molecule GLP-1 receptor agonist CT-996, thiab GLP-1/GIP receptor dual receptors CT-888.
Tilpotide tau npaj yuav suav nrog hauv cov kev kho mob tshiab rau kev kho cov kab mob metabolic cuam tshuam rau lub siab rog.
Thaum Lub Ib Hlis 21, 2026, lub vev xaib raug cai ntawm Lub Chaw Rau Tshuaj Ntsuam Xyuas Tshuaj (CDE) ntawm National Medical Products Administration (NMPA) tshaj tawm tias Eli Lilly's GIP / GLP-1 dual receptor agonist, Puerpotide, yog npaj los suav nrog hauv kev kho mob rau kev kho mob ntawm cov kab mob metabolic cuam tshuam rau lub siab rog.
Thaum Lub Rau Hli 2024, Eli Lilly tau tshaj tawm cov ntsiab lus ntxaws ntxaws ntawm Phase I SYNERGY-NASH txoj kev tshawb fawb txog kev kho mob metabolic txuam nrog steatohepatitis (MASH) cov neeg mob nrog cilapotide. Txoj kev tshawb no suav nrog 190 yam (nrog lossis tsis muaj ntshav qab zib hom 2) nrog rau theem 2 lossis 3 fibrosis uas tau ua pov thawj tias yog MASH los ntawm kev kuaj ntshav.
Qhov kev kwv yees cov hom phiaj ua tau zoo tau pom tias 51.85%, 62.8%, thiab 73.3% ntawm cov neeg kawm hauv 5mg, 10mg, thiab 15mg pawg ntawm Puerpeptide, raws li, tau ua tiav kev tshem tawm ntawm MASH hauv daim siab histology yam tsis muaj kev mob fibrosis tom qab 52 lub lis piam ntawm kev kho mob, thaum qhov kev faib ua feem ntawm cov pab pawg thib ob yog qhov kawg ntawm cov placebo. Cov ntaub ntawv no yuav raug nthuav tawm ntawm 2024 Lub Rooj Sib Tham Txhua Xyoo ntawm European Association rau Kev Tshawb Fawb Txog Kab Mob Siab (EASL) thiab tseem tau tshaj tawm hauv New England Journal of Medicine (NEJM).
Jixing Pharmaceutical tau ua tiav 2 billion yuan D1 puag ncig ntawm nyiaj txiag los tsim lub qhov ncauj me me molecule GLP-1 agonists
Thaum Lub Ib Hlis 22, 2026, hauv New Jersey, Corxel Pharmaceuticals Limited (Corxel), lub chaw kho mob theem biopharmaceutical tuam txhab mob siab rau tsim kho tshiab rau cov neeg mob plawv thiab cov kab mob metabolic thoob ntiaj teb, tshaj tawm txoj kev ua tiav ntawm nws qhov D1 puag ncig ntawm cov nyiaj, nce txog $ 287 lab (RM). Cov nyiaj tau los ntawm qhov kev pab nyiaj no yuav tsum txhawb nqa kev txhim kho ntawm CX11, tseem hu ua VCT220, qhov sib txawv ntawm qhov ncauj me me molecule GLP-1 receptor agonist rau cov neeg rog rog thiab rog. Tam sim no nws tau raug soj ntsuam hauv theem 2 kev sim ntawm CORXEL hauv Tebchaws Meskas thiab theem 3 kev sim ntawm Vincentiage hauv Suav teb, nrog rau lwm cov phiaj xwm kev mob plawv, suav nrog mob stroke ischemic thiab kub siab. Jixing Pharmaceutical tau tsim los ntawm RTW hauv 2019 thiab ua tiav $ 162 lab Series D nyiaj txiag hauv 2024. Bayer thiab RTW tau nqis peev $ 35 lab thiab $ 127 lab raws li Jixing Pharmaceutical Technology (Shanghai) Co., Ltd.